Pliant Therapeutics Inc. (PLRX): Price and Financial Metrics

Pliant Therapeutics Inc. (PLRX): $12.87

0.34 (+2.71%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add PLRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#258 of 341

in industry

PLRX Price/Volume Stats

Current price $12.87 52-week high $20.23
Prev. close $12.53 52-week low $10.29
Day low $12.32 Volume 503,900
Day high $12.99 Avg. volume 473,218
50-day MA $12.27 Dividend yield N/A
200-day MA $14.59 Market Cap 776.40M

PLRX Stock Price Chart Interactive Chart >


Pliant Therapeutics Inc. (PLRX) Company Bio


Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.


PLRX Latest News Stream


Event/Time News Detail
Loading, please wait...

PLRX Latest Social Stream


Loading social stream, please wait...

View Full PLRX Social Stream

Latest PLRX News From Around the Web

Below are the latest news stories about PLIANT THERAPEUTICS INC that investors may wish to consider to help them evaluate PLRX as an investment opportunity.

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

INTEGRIS-PSC interim results highlighted in an oral late-breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of preclinical data and clinical data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (P

Yahoo | November 13, 2023

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification Key Clinical Development and Regulatory appointments expand leadership team SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treat

Yahoo | November 9, 2023

Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?

Pliant Therapeutics (PLRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | November 9, 2023

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following November investor conferences. Stifel 2023 Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will

Yahoo | November 8, 2023

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 7, 2023

Read More 'PLRX' Stories Here

PLRX Price Returns

1-mo 13.39%
3-mo 8.33%
6-mo -24.91%
1-year -27.08%
3-year -49.35%
5-year N/A
YTD -28.93%
2023 -6.31%
2022 43.19%
2021 -40.58%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!